ARA-290

Assumed mechanism: ARA-290 is modeled on the helix-B surface of erythropoietin and is thought to act as a selective agonist at the "innate repair receptor" (IRR), a proposed heterodimer of the EPO receptor (EPOR) and the beta-common receptor (CD131/βcR). This receptor is reported to be upregulated specifically in injured or inflamed tissue and largely absent in healthy cells, which is the proposed basis for a targeted, low-side-effect repair signal. Binding is theorized to trigger anti-apoptotic, anti-inflammatory (cytokine-dampening) and pro-regenerative signaling, with downstream effects on nociception (some work implicates TRPV1). The IRR's exact composition and even its existence as a discrete receptor remain debated in the literature, so this should be read as the assumed/working mechanism, not settled fact, even though ARA-290 itself has real human trial data.

Result tags: the first sarcoidosis dose-ranging trial is tagged mixed because corneal nerve fiber area improved at 4 mg while the placebo-corrected pain difference was not significant.

Adverse events

In trials, adverse events were mostly mild: transient injection-site reactions, occasional headache, mild GI discomfort. Crucially, no clinically significant hematologic changes (no rise in hemoglobin/hematocrit), the whole design intent, and no anti-drug antibodies detected. The type 2 diabetes trial recorded 4 serious adverse events with 2 deemed possibly related but with uncertain causality, in an older, comorbid diabetic population; this is the main asterisk on an otherwise clean short-term profile.

Contraindications

Not an approved drug, so there are no formal contraindications, only prudent ones. Caution/avoidance is reasonable in active or recent cancer (pro-survival signaling, unproven relevance), pregnancy and breastfeeding (no data), and anyone unable to verify product identity/purity from a research-peptide vendor. Diabetics or those on glucose-lowering or lipid therapy should note the small metabolic effects seen in trials and monitor accordingly. Unlike erythropoietin itself, it is not expected to be contraindicated in uncontrolled hypertension, but that rests on mechanism plus short-term data, not long-term safety studies.

Theoretical concerns

Mechanistically reassuring on the classic EPO worry: because ARA-290 is engineered NOT to activate the homodimeric EPO receptor that drives red-cell production, it should not raise hematocrit, blood pressure, or thrombosis risk the way EPO does, and trials support that. Residual theoretical concerns: the IRR triggers anti-apoptotic and pro-survival/repair signaling, so the open (unproven in humans) question is whether chronic, long-term, unsupervised agonism could be unfavorable in the setting of occult malignancy or unwanted tissue proliferation. No human signal for this exists, but no long-term human data exists either.

What nobody knows yet

The big unknowns are duration and source. Human exposure in trials capped at roughly 28 days (some IV pilots ~4 weeks); there is no controlled data on months-to-years of self-administration as used in the gray market. Long-term safety, repeat-cycle safety, and effects outside the two trialed neuropathy populations are simply not established. On top of that, gray-market product carries the usual unknowns: actual peptide identity, purity, correct sequence, endotoxin, and accurate dosing, none of which the clinical safety record covers.

What else could explain the result

In the community, ARA-290 is very commonly stacked with BPC-157 and/or TB-500 for "nerve and tissue repair," and frequently layered onto an existing regimen of better glycemic control, anti-inflammatory diet changes, physical therapy, or other peptides. Sarcoidosis and diabetic neuropathy also wax and wane on their own. Any single-user "it worked" report is therefore heavily confounded, attribution to ARA-290 specifically is rarely clean, and there is no clinical data on the combination stacks people actually run.

Is the vial what it says?

Verified across registered clinical trials and peer-reviewed literature: ClinicalTrials.gov NCT02039687 (Araim Pharmaceuticals, Phase 2, sarcoidosis SFN, n=64, completed); Heij et al. (Mol Med 2012, sarcoidosis pilot); Brines et al. (Mol Med 2015, type 2 diabetes); Culver et al. (IOVS 2017, corneal nerve fiber). Pharmacokinetics (terminal half-life ~20 min SC) sourced from the published type 2 diabetes trial. No FDA approval found on DailyMed.

Half-life and storage

Half-life: Very short in plasma: terminal half-life roughly 20 minutes after subcutaneous dosing (peak ~3 ng/mL after 4 mg SC), and only ~2 minutes after IV. The clinical effects (nerve regrowth, symptom relief over weeks) far outlast drug presence in blood, consistent with a receptor-triggered repair cascade rather than sustained circulating exposure, a key reason once-daily dosing was used despite the brief half-life.

Once mixed: As a peptide it is supplied lyophilized and is handling-sensitive. Store lyophilized powder refrigerated (2-8 C) and protected from light; reconstitute gently with bacteriostatic or sterile water (do not shake vigorously). Use reconstituted solution promptly, within ~24 hours if held at room temperature, and refrigerate reconstituted material, avoiding freeze-thaw cycles. Gray-market product also carries unverified starting purity and content, which compounds any handling degradation.

What people report

Volume of reports: faint. Little real-world record, or mostly noise.

Low. Despite being one of the more legitimately studied peptides, organic community discussion is thin, searches surface mostly clinical literature plus vendor and practitioner-clinic marketing pages rather than large volumes of first-person user reports on forums. It is a niche compound used for a niche problem (neuropathy), so it lacks the broad biohacker chatter of BPC-157 or GLP-1 drugs.

Mixed and hard to read. Where anecdote exists, people with genuine neuropathic pain sometimes report gradual reductions in burning/tingling and better autonomic symptoms over weeks; others report little or nothing, and effects are described as subtle and slow rather than dramatic. Because it is so often stacked with BPC-157/TB-500 and lifestyle changes, even positive reports are inconsistent and confounded.

Weak as anecdote, but the underlying science is unusually credible for this category. Much of the favorable online content is affiliate/vendor or clinic marketing and should be discounted. The trustworthy signal here comes from the published Phase 2 trials (objective corneal-nerve and metabolic endpoints), not from forum testimonials, which is the opposite of most gray-market peptides where only anecdote exists.

• Reported as a 'feel-nothing-then-gradually-better' compound for nerve pain, users with diabetic or idiopathic small-fiber neuropathy describe slow, subtle reductions in burning, tingling, or numbness over weeks rather than any acute effect (anecdote, not proof).
• Commonly run alongside BPC-157 and/or TB-500 for nerve and soft-tissue 'repair' stacks, which makes individual attribution to ARA-290 very murky (anecdote).
• Frequently praised for a clean tolerability profile, people note minimal side effects beyond occasional injection-site irritation, consistent with the trial data (anecdote).
• A meaningful share of users report little to no perceptible benefit, and some question whether gray-market product is the correct, pure peptide at all, disappointment and source-skepticism are recurring themes (anecdote).

Reports are anecdote, not proof.

Can you tell if it is working?

First documented human use: First documented human exposure dates to approximately 2009-2011. The earliest published controlled trial (Heij et al., Molecular Medicine, received Nov 2012) tested IV ARA 290 in 22 sarcoidosis patients and explicitly references pre-existing safety data from healthy volunteers and patients with kidney disease and diabetes, so first-in-human dosing preceded that publication. Unlike most gray-market peptides, ARA-290 HAS completed controlled human trials, the blank here is not "no human data" but "no Phase 3 and no regulatory approval."

1. ~2008-2010Helix-B surface peptide / ARA 290 developed (Brines, Cerami and colleagues) to separate EPO's tissue-protective signaling from erythropoiesis; Araim Pharmaceuticals advances it as cibinetide. First-in-human dosing in this window.
2. 2012First controlled human trial published: IV ARA 290 in 22 sarcoidosis patients with small-fiber neuropathy (Heij et al., Molecular Medicine), well tolerated, symptom improvement.
3. 2013Phase 2 sarcoidosis RCT (Dahan et al., 38 enrolled) reports increased corneal nerve fiber density sustained at follow-up.
4. 2014-2015Phase 2b dose-ranging sarcoidosis trial (NCT02039687, n=64) completed; Phase 2 type 2 diabetes neuropathy/metabolic trial (Brines et al., 2015) published.
5. 2017Culver et al. (IOVS) report placebo-corrected increase in corneal nerve fiber area at the 4 mg dose, a key objective regeneration signal.
6. 2020Phase 2 trial of cibinetide for diabetic macular edema (9 patients, 12 weeks, 4 mg daily) found no improvement in vision or retinal thickness and no serious adverse events. No cibinetide trials are currently active.
7. 2020sClinical program does not advance to a completed Phase 3; no FDA approval. Compound migrates into the gray/research-peptide market and practitioner clinics for off-label nerve and inflammation use.

• ClinicalTrials.gov NCT02039687. Phase 2 sarcoidosis SFN dose-ranging (Araim, n=64, completed)(Primary registered trial; confirms sponsor, phase, doses (1/4/8 mg SC), enrollment, completion 2015.)
• PubMed, cibinetide / ARA-290 (all results)(Master list separating human Phase 2 trials (sarcoidosis, T2D, diabetic macular edema) from animal/in-vitro work.)
• Heij et al. 2012, ARA 290 in sarcoidosis, randomized double-blind pilot (Mol Med; PMID 23168581)(Earliest controlled human trial; anchors first-documented-human-use timeline (~2010-2012).)
• Brines et al. 2015, ARA 290 in type 2 diabetes (Mol Med; PMID 25387363)(Phase 2 RCT; source of PK (t1/2 ~20 min SC), PainDetect, HbA1c/lipid, and the 4 SAEs/no-ADA safety detail.)
• Culver et al. 2017, cibinetide and corneal nerve fiber abundance (IOVS; PMID 28475703)(Phase 2b dose-ranging sarcoidosis trial; 4 mg dose increased corneal nerve fiber area.)
• Lois et al. 2020, Phase 2 cibinetide in diabetic macular edema (J Clin Med; PMID 32674280)(9 patients, no improvement in vision or retinal thickness, no serious adverse events.)
• PubMed, cibinetide / ARA-290 preclinical (animal/in-vitro)(Supports that broader anti-inflammatory/autoimmune/repair claims are animal-stage only (Grade D).)
• DailyMed, cibinetide search (no approved label)(Confirms no FDA-approved product; compound remains investigational.)
• Heij L, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med 2012. PMID 23168581(dose table)
• Dahan A, et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med 2013;19:334-45. PMID 24136731(dose table)
• Culver DA, et al. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain. Invest Ophthalmol Vis Sci 2017;58(6):BIO52-BIO60. PMID 28475703; arms and route per ClinicalTrials.gov NCT02039687(dose table)
• Brines M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med 2015;20:658-66. PMID 25387363(dose table)
• Lois N, et al. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. J Clin Med 2020;9(7):2225. PMID 32674280(dose table)